Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clec4d-neutralising antibody
- Development stage
- Preclinical
- Lead developer
- University of Edinburgh
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Clec4d-neutralising antibody is a preclinical monoclonal antibody being developed by the University of Edinburgh for the treatment of organ fibrosis, specifically kidney fibrosis. It targets C-type lectin domain family 4 member D (CLEC4D, also known as MCL), a pattern recognition receptor predominantly expressed on myeloid cells, including a novel population of pro-inflammatory and pro-fibrotic Arginase-1-positive (Arg1+) scar-associated monocyte-derived macrophages. By neutralizing CLEC4D, the antibody inhibits the activation and pro-fibrotic signaling of these macrophages, leading to a decrease in Arg1 and other fibrosis-related gene expression, thereby limiting the progression of progressive kidney disease and tissue scarring.
- Other names
- CLEC4D-neutralising antibodyCLEC-4D-neutralising antibodyCLEC 4D-neutralising antibodyCLEC4D-neutralizing antibodyCLEC-4D-neutralizing antibodyCLEC 4D-neutralizing antibodyanti-CLEC4D antibodyanti-CLEC-4D antibodyanti-CLEC 4D antibody
02
Targets
CLEC4D (C-type lectin domain family 4 member D)
Beyond the preview
Go deeper on Clec4d-neutralising antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Clec4d-neutralising antibody.